A Phase 1/2a Trial of CLN-081 in Patients With Non-Small Cell Lung Cancer
Status:
Recruiting
Trial end date:
2022-03-15
Target enrollment:
Participant gender:
Summary
CLN-081-101 is a Phase 1/2a, open label, multi-center study of CLN-081 in patients with NSCLC
(non small cell lung cancer) harboring EGFR (epidermal growth factor receptor) exon 20
insertion mutations, to determine the maximum tolerated dose (MTD) and recommended Phase 2
dose (RP2D), as well as to evaluate preliminary efficacy.